NCT07413640 Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors
| NCT ID | NCT07413640 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central Hospital, Nancy, France |
| Condition | Liver Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-02-02 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2026-02-02 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Microwave ablation is a minimally invasive technique whose planning relies on manufacturer tables derived from ex vivo models that do not account for patient or tumor-specific factors. In clinical practice, the actual ablation volume often differs from the planned volume due to liver characteristics, vascular proximity, and tumor biology. This study aims to assess the variability between ablation small axis during percutaneous microwave ablation of liver lesions. The influence of patient-related (fibrosis, steatosis, portal flow) and tumor-related factors (location, histology, prior treatment) will be evaluated. Small axis and volume will be compared with volumes measured on immediate post-procedural CT and on CT/MRI at 6-12 weeks, accounting for expected tissue shrinkage.
Eligibility Criteria
Inclusion Criteria: * Adult patients * Treated with percutaneous hepatic microwave ablation under CT or ultrasound guidance * Adult treated for one or more liver lesions * Patients with available follow-up imaging Exclusion Criteria: * Two treatment cycles on the same lesion during the same session. * Reoperation on the same lesion. * Planned volume not available (no manufacturer data, not specified in the surgical report). * No control imaging injected between 1 and 4 months post-procedure. * Final ablation volume not measurable (e.g., artifacts, no injection on MRI). * No definitive diagnosis of the nature of the tumor on imaging and no histology available.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07413640 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Liver Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07413640 currently recruiting?
Yes, NCT07413640 is actively recruiting participants. Contact the research team at v.laurent@chru-nancy.fr for enrollment information.
Where is the NCT07413640 trial being conducted?
This trial is being conducted at Vandœuvre-lès-Nancy, France.
Who is sponsoring the NCT07413640 clinical trial?
NCT07413640 is sponsored by Central Hospital, Nancy, France. The trial plans to enroll 90 participants.